144 related articles for article (PubMed ID: 18654595)
1. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas).
Rakha EA; Ellis IO; Reis-Filho JS
Mod Pathol; 2008 Aug; 21(8):1060-1; author reply 1061-2. PubMed ID: 18654595
[No Abstract] [Full Text] [Related]
2. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas).
Lerma E; Peiro G; Ramón T; Fernandez S; Martinez D; Pons C; Muñoz F; Sabate JM; Alonso C; Ojeda B; Prat J; Barnadas A
Mod Pathol; 2007 Nov; 20(11):1200-7. PubMed ID: 17885672
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
4. Comparison Between HER2, Estrogen Receptors and Progesterone Receptors in Primary Breast Carcinomas and Matched Lymph Node Metastases.
Desouki MM; Atta IS; Wolff DJ; Self SE
Turk Patoloji Derg; 2016; 32(3):178-85. PubMed ID: 27562392
[TBL] [Abstract][Full Text] [Related]
5. Invasive breast cancer: a significant correlation between histological types and molecular subgroups.
Caldarella A; Buzzoni C; Crocetti E; Bianchi S; Vezzosi V; Apicella P; Biancalani M; Giannini A; Urso C; Zolfanelli F; Paci E
J Cancer Res Clin Oncol; 2013 Apr; 139(4):617-23. PubMed ID: 23269487
[TBL] [Abstract][Full Text] [Related]
6. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.
Khande TA; Joshi AR; Khandeparkar SGS; Kulkarni MM; Gogate BP; Kakade AR; Sahu PD; Khillare CD
Indian J Cancer; 2020; 57(2):190-197. PubMed ID: 32445323
[TBL] [Abstract][Full Text] [Related]
7. Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: correlation with histologic sections determinations and diagnostic pitfalls.
Moriki T; Takahashi T; Ueta S; Mitani M; Ichien M
Diagn Cytopathol; 2004 Apr; 30(4):251-6. PubMed ID: 15048960
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu.
Bouras T; Southey MC; Venter DJ
Cancer Res; 2001 Feb; 61(3):903-7. PubMed ID: 11221879
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
[TBL] [Abstract][Full Text] [Related]
10. Breast carcinoma in Uganda: microscopic study and receptor profile of 45 cases.
Roy I; Othieno E
Arch Pathol Lab Med; 2011 Feb; 135(2):194-9. PubMed ID: 21284437
[TBL] [Abstract][Full Text] [Related]
11. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.
Liu C; Zhang H; Shuang C; Lu Y; Jin F; Xu H; Lu P
Med Oncol; 2010 Sep; 27(3):747-52. PubMed ID: 19657752
[TBL] [Abstract][Full Text] [Related]
12. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas.
Lal P; Tan LK; Chen B
Am J Clin Pathol; 2005 Apr; 123(4):541-6. PubMed ID: 15743737
[TBL] [Abstract][Full Text] [Related]
13. Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer.
Anderson WF; Rosenberg PS; Katki HA
J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24777110
[No Abstract] [Full Text] [Related]
14. Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia.
Arafah M
Turk Patoloji Derg; 2012; 28(1):38-43. PubMed ID: 22207430
[TBL] [Abstract][Full Text] [Related]
15. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.
Niemeier LA; Dabbs DJ; Beriwal S; Striebel JM; Bhargava R
Mod Pathol; 2010 Feb; 23(2):205-12. PubMed ID: 19898421
[TBL] [Abstract][Full Text] [Related]
17. Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas.
Cimino-Mathews A; Subhawong AP; Elwood H; Warzecha HN; Sharma R; Park BH; Taube JM; Illei PB; Argani P
Hum Pathol; 2013 Jun; 44(6):959-65. PubMed ID: 23260325
[TBL] [Abstract][Full Text] [Related]
18. [Expression of estrogen and progesterone receptors and HER-2 by breast cancer cells].
Zaĭrat'iants OV; Kolobov SV; Akopian IG; Opalenov KV; Barsanova TG
Arkh Patol; 2004; 66(5):9-12. PubMed ID: 15575377
[TBL] [Abstract][Full Text] [Related]
19. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.
Allred DC
Mod Pathol; 2010 May; 23 Suppl 2():S52-9. PubMed ID: 20436503
[TBL] [Abstract][Full Text] [Related]
20. Expression of tight junction protein claudin-4 in basal-like breast carcinomas.
Kulka J; Szász AM; Németh Z; Madaras L; Schaff Z; Molnár IA; Tokés AM
Pathol Oncol Res; 2009 Mar; 15(1):59-64. PubMed ID: 18752049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
